The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Platinum-based chemotherapy remains the standard-of-care for most patients affected by
advanced non-small cell lung cancer (NSCLC). The platinum compounds currently used in …

Background Because the efficacy of carboplatin and cisplatin in the treatment of advanced
non–small-cell lung cancer (NSCLC) has not been proven to be equivalent, an individual …

Objectives Platinum-based chemotherapy is the mainstay of first-line (1L) therapy for
advanced non-small cell cancer (NSCLC). The objective of this study was to evaluate the …

The use of chemotherapy is considered standard therapy in patients with locally advanced
non-small-cell lung cancer that cannot be treated with radiotherapy and in those with …

Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since
the late 1970s. Current evidence suggests that it may be the most effective single drug for …

Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients
With Advanced Non–Small-Cell Lung C Page 1 Meta-Analysis of Randomized Clinical Trials …

Cisplatin is one of the most potent anticancer agents, displaying significant clinical activity
against a variety of solid tumors. For more than two decades, the most effective systemic …

Management of patients with lung cancer continues to pose a considerable challenge to
today's oncologist. While treatment may be curative in the early stages of the disease, the …

The treatment of advanced non-small cell lung cancer (NSCLC) has continued to evolve
over recent years. We have moved from an era of therapeutic nihilism to optimism, largely …